Canaccord Genuity Upgrades Sarepta Therapeutics To Buy

Canaccord Genuity upgraded

from Hold to Buy. The price target for Sarepta Therapeutics has been raised from $16.00 to $30.00. Sarepta Therapeutics shares have dropped 47.40 percent over the past 52 weeks, while the S&P 500 index has surged 12.70 percent in the same period. Sarepta Therapeutics' shares rose 45.30 percent to $23.80 in pre-market trading.